| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Obstetrics and Gynecology, University of Hamburg, Hamburg, Germany [K. F., B-W. L., G. K., F. H., H. M.]; Department of Pathology, University of Giessen, Giessen, Germany [F. F., I. G., H-J. T.]; and Basel Institute for Immunology, Grenzacherstrasse 487, CH-4005 Basel, Switzerland [U. G.]
CD44 is a transmembrane glycoprotein occurring in several isoforms with different extracellular regions. The various transcripts are encoded by one gene locus containing 20 exons, of which at least 10 can be alternatively spliced in nascent RNA. Isoforms encoded by the variant exons (termed CD44v) are highly restricted in their distribution in non-malignant tissue as opposed to the standard form of CD44 (CD44s) abundant in many tissues. Specific variant isoforms containing exon 6v have been shown to render nonmetastatic rat tumor cells metastatic. Based on the prominent role in rat metastasis formation, CD44v isoforms were suggested to be involved in human tumor progression. Correlations between prognosis and expression of CD44v have been reported for gastric and colon carcinoma, for non-Hodgkin's lymphoma, and recently for breast carcinoma. We evaluated the expression of CD44 isoforms in node-positive (n = 119) and node-negative (n = 108) cases of breast carcinoma by immunohistochemistry using CD44v exon-specific mAbs. In a subset of 43 cases of high-risk patients, reverse transcription-PCR was used to determine the exon composition of the transcripts. Protein and RNA expression data were probed statistically for their correlation to survival of the patients and clinical risk factors. In contrast to recently published data (M. Kaufmann et al., Lancet, 345: 615–619, 1995), in our cohort disease-free and overall survival data did not indicate significant correlations with the expression of the analyzed isoforms in univariate and multivariate analyses. Comparison of CD44 protein expression with established clinical risk factors for survival such as tumor size (pT1 + pT2) and histological grading revealed correlations with the presence of CD44s (P = 0.02 and P = 0.03, respectively) and CD44-9v (P = 0.05 for histological grading). Carcinoma tissues with elevated estrogen and progesterone receptor levels showed positive correlation with CD44-6v (P = 0.001), while a trend for significant coexpression of CD44s and CD44-9v isoforms was observed in estrogen receptor-positive tissues (P = 0.08 and 0.06, respectively). In breast cancer, CD44s, CD44-9v, and CD44-6v are apparently markers for cellular differentiation but not for tumor progression. Our data suggest that steroid hormone receptors may be associated with the in vivo expression of CD44-6v-containing isoforms in human mammary carcinoma.
1 To whom requests for reprints should be addressed, at Basel Institute for Immunology, Grenzacherstrasse 487, CH-4005 Basel, Switzerland, Phone: (+41) 61 605 1111; Fax (+41) 61 605 1222. E-mail: Guenthert@bii.ch. The Basel Institute for Immunology was founded and is supported by F. Hoffmann LaRoche Ltd., Basel, Switzerland.
Received 5/17/95. Accepted 9/ 8/95.
This article has been cited by other articles:
|
|
 |
|
  S. B. Wallach-Dayan, A. M. Rubinstein, C. Hand, R. Breuer, and D. Naor DNA vaccination with CD44 variant isoform reduces mammary tumor local growth and lung metastasis Mol. Cancer Ther., June 1, 2008; 7(6): 1615 - 1623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ouhtit, Z. Y. Abd Elmageed, M. E. Abdraboh, T. F. Lioe, and M. H.G. Raj In Vivo Evidence for the Role of CD44s in Promoting Breast Cancer Metastasis to the Liver Am. J. Pathol., December 1, 2007; 171(6): 2033 - 2039. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G M K Tse, P-H Tan, T K F Ma, C B Gilks, C S P Poon, and B K B Law CD44s is useful in the differentiation of benign and malignant papillary lesions of the breast J. Clin. Pathol., November 1, 2005; 58(11): 1185 - 1188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. K. Diaz, X. Zhou, E. T. Wright, M. Cristofanilli, T. Smith, Y. Yang, N. Sneige, A. Sahin, and M. Z. Gilcrease CD44 Expression Is Associated with Increased Survival in Node-Negative Invasive Breast Carcinoma Clin. Cancer Res., May 1, 2005; 11(9): 3309 - 3314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Okamoto, H. Tsuiki, L. C. Kenyon, A. K. Godwin, D. R. Emlet, M. Holgado-Madruga, I. S. Lanham, C. J. Joynes, K. T. Vo, A. Guha, et al. Proteolytic Cleavage of the CD44 Adhesion Molecule in Multiple Human Tumors Am. J. Pathol., February 1, 2002; 160(2): 441 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Karjalainen, R. H. Tammi, M. I. Tammi, M. J. Eskelinen, U. M. Agren, J. J. Parkkinen, E. M. Alhava, and V.-M. Kosma Reduced Level of CD44 and Hyaluronan Associated with Unfavorable Prognosis in Clinical Stage I Cutaneous Melanoma Am. J. Pathol., September 1, 2000; 157(3): 957 - 965. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Hebbard, A Steffen, V Zawadzki, C Fieber, N Howells, J Moll, H Ponta, M Hofmann, and J Sleeman CD44 expression and regulation during mammary gland development and function J. Cell Sci., January 7, 2000; 113(14): 2619 - 2630. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Rodriguez-Rodriguez, I. Sancho-Torres, D. G. Gibbon, L. F. Miller Watelet, and C. Mesonero CD44-9v and CD44-10v Are Potential Molecular Markers for Squamous Cell Carcinoma of the Vulva Reproductive Sciences, January 1, 2000; 7(1): 70 - 75. [Abstract] [PDF]
|
|
|
|
|
|
K. Aogi, K. Kitahara, V. Urquidi, D. Tarin, and S. Goodison Comparison of Telomerase and CD44 Expression as Diagnostic Tumor Markers in Lesions of the Thyroid Clin. Cancer Res., October 1, 1999; 5(10): 2790 - 2797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kayastha, A. N., F. M., S. Piver, J. Mukkamalla, M. Romero-Guittierez, and B. A. Werness Expression of the Hyaluronan Receptor, CD44S, in Epithelial Ovarian Cancer Is an Independent Predictor of Survival Clin. Cancer Res., May 1, 1999; 5(5): 1073 - 1076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Roca, J. L. Mate, A. Ariza, A. M. Munoz-Marmol, C. von Uexkull-Guldeband, I. Pellicer, J. J. Navas-Palacios, and M. Isamat CD44 Isoform Expression Follows Two Alternative Splicing Pathways in Breast Tissue Am. J. Pathol., July 1, 1998; 153(1): 183 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Kogerman, M.-S. Sy, and L. A. Culp Overexpressed human CD44s promotes lung colonization during micrometastasis of murine fibrosarcoma cells: Facilitated retention in the lung vasculature PNAS, November 25, 1997; 94(24): 13233 - 13238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Schmits, J. Filmus, N. Gerwin, G. Senaldi, F. Kiefer, T. Kundig, A. Wakeham, A. Shahinian, C. Catzavelos, J. Rak, et al. CD44 Regulates Hematopoietic Progenitor Distribution, Granuloma Formation, and Tumorigenicity Blood, September 15, 1997; 90(6): 2217 - 2233. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
